click below
click below
Normal Size Small Size show me how
MDCO
Preparation for job with new company
Question | Answer |
---|---|
Which products are currently in the MDCO Pipeline? | Cangrelor, Ionsys, Oritavancin, MDCO-216, Aln-PCSK |
What is Cangrelor? | An Investigational antiplatelet agent. |
What is Ionsys? | An investigational fentanyl Iontophoretic transdermal system. |
What is MDCO-216? | An investigational, reverse cholesterol transport that is a naturally occurring variant of a protein called ApoA-1 found in human high -density lipoprotein. |
What is Recothrom? | A Topical Thrombin. |
What is Recothrom indicated for? | It is indicated to aid hemostasis whenever oozing blood and minor bleeding from capillaries and small venues is accessible and control of bleeding by standard surgical techniques is ineffective or impractical in adult and pediatric populations. |
Cleviprex (clevidipine) | A dihydropyridine calcium channel blocker indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable. |
Carbavance | Investigational antibiotic. Designated by the FDA on 1/13/14 as a "Qualified Infectious Disease Poduct (QIPD). This designation provides a priority review by the FDA and is eligible for fast track status. |
Boston Scientific and MDCO Announce U.S. Co-Promotion | The Promus Premier stent System. |
Rempex Pharmaceuticals | Acquired by MDCO in December of 2013. A company with multiple potential new therapies focused on multi-drug resistant gram-negative bacteria. |
Oritivancin | An investigational antibiotic in development for the treatment of acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria. |